Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.72 |
| ▸ | PNMT | P11086 | 9/20 | 0.61 |
| ▸ | PRCP | P42785 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30156803 | 1.00 | CD44 (0.72) | CD44PNMTPRCPMAOBADRA2A | |
| Hydrochloric Acid SCHEMBL4516826 | 0.98 | CD44 (0.70) | CD44PNMTPRCPMAOBADRA2A | |
| SCHEMBL11327051 | 0.89 | CD44 (0.62) | CD44PNMTPRCPMAOBHTR2C | |
| SCHEMBL509247 | 0.86 | CD44 (0.75) | CD44PNMTPRCPMAOBHTR2C | |
| SCHEMBL29771844 | 0.84 | CD44 (1.00) | CD44PNMTPRCPMAOBHTR2C | |
| SCHEMBL329571 | 0.84 | CD44 (1.00) | CD44PNMTPRCPMAOBHTR2C | |
| Hydrochloric Acid SCHEMBL4506036 | 0.82 | CD44 (0.96) | CD44PNMTPRCPMAOBHTR2C | |
| Hydrochloric Acid SCHEMBL4520528 | 0.82 | CD44 (0.96) | CD44PNMTPRCPMAOBHTR2C | |
| SCHEMBL329619 | 0.81 | CD44 (0.68) | CD44PNMTPRCPMAOB | |
| SCHEMBL29805405 | 0.81 | CD44 (0.68) | CD44PNMTPRCPMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632948-B2 | Method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives | NEUROSEARCH A/S (DK) | 2009-12-15 | — | — | US | claimed |
| US-20060178391-A1 | Method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives | NEUROSEARCH A/S (DK) | 2006-08-10 | — | — | US | claimed |
| EP-1532146-B1 | A METHOD OF PREPARING ENANTIOMERS OF INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH AS (DK) | 2006-03-01 | — | — | EP | claimed |
| EP-1532146-A2 | A METHOD OF PREPARING ENANTIOMERS OF INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH A/S (DK) | 2005-05-25 | — | — | EP | claimed |
| WO-2004018466-A2 | A METHOD OF PREPARING ENANTIOMERS OF INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH A/S (DK) | 2004-03-04 | — | — | WO | claimed |
| EP-4651955-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20240293392-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-09-05 | — | — | US | disclosed |
| WO-2024153947-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-07-25 | — | — | WO | disclosed |
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ZOETIS LLC | 2024-05-09 | — | — | US | disclosed |
| CN-117693507-A | Inhibitor compounds | 奈奥芬莱有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4291555-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-116806218-A | Sulfonamide and its use for the treatment of parasitic helminth infections and diseases | 新基公司 | 2023-09-26 | — | — | CN | disclosed |
| EP-0074741-A1 | Method of producing alpha2 antagonism | SMITHKLINE BECKMAN CORPORATION (US) | 1983-03-23 | — | — | EP | disclosed |
| US-4352809-A | THIADIAZOLO- AND OXADIAZOLOTETRAHYDROISOQUINOLINES, ANTIDEPRESSANTS | SMITHKLINE CORPORATION (US) | 1982-10-05 | — | — | US | disclosed |
| US-4258049-A | Inhibiting phenylethanolamine N-methyltransferase with thiadiazolo and oxadiazolotetrahydroisoquinolines | SMITHKLINE CORPORATION (US) | 1981-03-24 | — | — | US | disclosed |
| EP-0023761-A1 | Tetrahydroisoquinoline derivatives, process for preparing them and compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1981-02-11 | — | — | EP | disclosed |
| US-4228170-A | INHIBITOR OF PHENYLETHANOLAMINE N-METHYLTRANSFERASE | SMITHKLINE CORPORATION (US) | 1980-10-14 | — | — | US | disclosed |
| US-4062961-A | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES | SMITHKLINE CORPORATION (US) | 1977-12-13 | — | — | US | disclosed |
| US-4022900-A | Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents | MARION LABORATORIES, INC. (US) | 1977-05-10 | — | — | US | disclosed |
| US-3988339-A | 7 OR 8-SUBSTITUTED 1,2,3,4-TETRAHYDRO-ISOQUINOLINE | SMITHKLINE CORPORATION (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293392-A1 | INHIBITOR COMPOUNDS | MSH2, PMS2, MSH6 | CD44 3770/4885PNMT 1748/4885PRCP 2632/4885 |
| US-20060178391-A1 | Method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives | IDO2, IDO1, TPH2 | CD44 4587/4885PNMT 109/4885PRCP 3648/4885 |
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ARSA, MRPS2, SULT2A1 | CD44 2319/4885PNMT 554/4885PRCP 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.